Scarica l'app Stockscreener
1.19
0.83%
-0.01
Dopo l'orario di chiusura:
1.23
0.04
+3.36%
Precedente Chiudi:
$1.20
Aprire:
$1.24
Volume 24 ore:
60,471
Relative Volume:
0.38
Capitalizzazione di mercato:
$31.28M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-0.83%
1M Prestazione:
+4.39%
6M Prestazione:
-10.53%
1 anno Prestazione:
-41.67%
Intervallo 1D:
$1.15
$1.27
Intervallo di 1 settimana:
$1.09
$1.28
Portata 52W:
$1.02
$2.40
Rein Therapeutics Inc Stock (RNTX) Company Profile
Nome
Rein Therapeutics Inc
Settore
Industria
Telefono
(737) 802-1989
Indirizzo
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.19 | 31.54M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-22 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2017-07-24 | Iniziato | BofA/Merrill | Buy |
| 2017-07-24 | Iniziato | Jefferies | Buy |
| 2017-07-24 | Iniziato | William Blair | Outperform |
Rein Therapeutics Inc Borsa (RNTX) Ultime notizie
With FDA hold lifted, IPF clinical trial of LTI-03 begins dosing patients - Pulmonary Fibrosis News
Rein Therapeutics doses first patient in IPF trial for LTI-03 - Investing.com Canada
Rein Therapeutics doses first patient in phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis - marketscreener.com
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis - GlobeNewswire
Rein Therapeutics Raises $2.3 Million in Private Unsecured Notes With 20% OID, Due by Jun 30, 2026 - TradingView
Chet Holmgren x Nike KD 18 "Thunder & Reign" Releases March 13th - Sneaker Bar Detroit
RNTX Technical Analysis & Stock Price Forecast - Intellectia AI
Rein Therapeutics Inc. announced that it has received $2.3 million in funding - marketscreener.com
White House to host Big Tech after pledge to rein in power costs - Yahoo Finance
Profit Recap: What are the future prospects of Sage Therapeutics Inc2025 Analyst Calls & Daily Entry Point Trade Alerts - baoquankhu1.vn
Rein Therapeutics Inc. announced that it expects to receive $2.3 million in funding - marketscreener.com
Targets Report: What makes Rein Therapeutics Inc stock attractive today2025 Technical Patterns & Smart Swing Trading Alerts - baoquankhu1.vn
Rein Therapeutics Announces Immediate Board Director Resignation - TipRanks
Rein Therapeutics (RNTX) director Aivado resigns from board role - Stock Titan
Quarterly Recap: How cyclical is The Nassau Companies of New York Preferred Securitys revenue streamEntry Point & Growth Oriented Trade Recommendations - baoquankhu1.vn
Rein Therapeutics Inc. Announces Manuel C. Alves Aivado Decides to Resign as Member of Board of Directors, Effective February 16, 2026 - marketscreener.com
Will Rein Therapeutics Inc. stock split again soon2025 Support & Resistance & Consistent Profit Trading Strategies - mfd.ru
Is Meteoric Resources NL (RNF) stock a buy for dividend portfoliosLayoff News & Verified Momentum Watchlists - mfd.ru
Stock Report: How correlated is Madrigal Pharmaceuticals Inc to the S P500Weekly Trade Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Why Sterling Infrastructure Inc. (UAO) stock appeals to dividend investors2025 Market Outlook & Free Fast Entry Momentum Trade Alerts - mfd.ru
Is Rein Therapeutics Inc. stock oversold or undervalued2025 Price Action Summary & Daily Stock Trend Watchlist - mfd.ru
KCK LTD. Adjusts Holdings in Sight Sciences Inc: A Strategic Por - GuruFocus
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - The Manila Times
IPO Launch: What is the target price for Vaxcyte Inc stockMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline - GlobeNewswire
Buy Signal: What is Sotera Health Companys valuation compared to sectorJobs Report & Target Return Focused Stock Picks - baoquankhu1.vn
Rein Therapeutics (RNTX) Price Target Increased by 25.00% to 10.20 - Nasdaq
Aug Sentiment: Is Rein Therapeutics Inc a speculative investmentJuly 2025 Chart Watch & Proven Capital Preservation Methods - baoquankhu1.vn
Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Up 76.0% in January - Defense World
KDA Group (CVE:KDA) Stock Price Up 23.5% – Still a Buy? - Defense World
Pinewood Technologies Group (LON:PINE) Shares Up 22.4% – What’s Next? - Defense World
Rein Therapeutics Inc. (RNTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Jones Trading initiates coverage on Rein Therapeutics stock with Buy rating - Investing.com Canada
Introducing Rein Security: Bringing Production Context to Application Security - Yahoo Finance
Smart Money: Can ASAN sustain earnings growthJuly 2025 Action & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Buy Signal: Is Rein Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Rally Mode: What is the target price for Inno Holdings Inc stockBear Alert & Accurate Buy Signal Alerts - baoquankhu1.vn
Inhaled IPF therapy LTI-03 awarded orphan drug status in Europe - Pulmonary Fibrosis News
RNTX: Analyst Downgrade by Brookline Capital to 'Hold' | RNTX St - GuruFocus
Brookline Capital Downgrades Rein Therapeutics(RNTX.US) to Hold Rating - 富途牛牛
Rein Therapeutics receives EMA orphan drug designation for IPF treatment By Investing.com - Investing.com Canada
Effort to rein in Wall Street landlords could push US home prices up, investors say - Yahoo Finance
Growth Report: Should I invest in LGCY before earningsTreasury Yields & Technical Entry and Exit Alerts - baoquankhu1.vn
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis - The Manila Times
NN, Inc. Appoints Ted White to Board of Directors - manilatimes.net
Corteva Agriscience Unveils Telbek™ PRO: First Group 21 Fungicide in Cereals, Tackling Fusarium Head Blight for Canadian Wheat Growers - The Manila Times
Titan Aviation Leasing Acquires Boeing 777-300ER to Support China Airlines’ Long-Haul Growth - The Manila Times
Fusemachines Announces Additional Investment by Existing Investor to Support Product Expansion and Client Growth - manilatimes.net
Rein Therapeutics Receives Orphan Drug Designation from - GlobeNewswire
Form 8-KMaterial Events - Stock Titan
Can Rein Therapeutics Inc. stock beat market expectations this quarterSector Performance Drivers & Maximum Profit Growth - bollywoodhelpline.com
Rein Therapeutics Inc Azioni (RNTX) Dati Finanziari
Non sono disponibili dati finanziari per Rein Therapeutics Inc (RNTX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):